Product Details for ANDA 214182
EVEROLIMUS (EVEROLIMUS)
2.5MG
Marketing Status: Prescription
5MG
Marketing Status: Prescription
7.5MG
Marketing Status: Prescription
10MG
Marketing Status: Prescription
2.5MG
Marketing Status: Prescription
Active Ingredient: EVEROLIMUS
Proprietary Name: EVEROLIMUS
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 2.5MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A214182
Product Number: 001
Approval Date: Feb 11, 2021
Applicant Holder Full Name: BIOCON PHARMA LTD
Marketing Status: Prescription
Patent and Exclusivity Information
EVEROLIMUS (EVEROLIMUS)
Proprietary Name: EVEROLIMUS
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 2.5MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A214182
Product Number: 001
Approval Date: Feb 11, 2021
Applicant Holder Full Name: BIOCON PHARMA LTD
Marketing Status: Prescription
Patent and Exclusivity Information
5MG
Marketing Status: Prescription
Active Ingredient: EVEROLIMUS
Proprietary Name: EVEROLIMUS
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 5MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A214182
Product Number: 002
Approval Date: Feb 11, 2021
Applicant Holder Full Name: BIOCON PHARMA LTD
Marketing Status: Prescription
Patent and Exclusivity Information
EVEROLIMUS (EVEROLIMUS)
Proprietary Name: EVEROLIMUS
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 5MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A214182
Product Number: 002
Approval Date: Feb 11, 2021
Applicant Holder Full Name: BIOCON PHARMA LTD
Marketing Status: Prescription
Patent and Exclusivity Information
7.5MG
Marketing Status: Prescription
Active Ingredient: EVEROLIMUS
Proprietary Name: EVEROLIMUS
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 7.5MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A214182
Product Number: 003
Approval Date: Feb 11, 2021
Applicant Holder Full Name: BIOCON PHARMA LTD
Marketing Status: Prescription
Patent and Exclusivity Information
EVEROLIMUS (EVEROLIMUS)
Proprietary Name: EVEROLIMUS
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 7.5MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A214182
Product Number: 003
Approval Date: Feb 11, 2021
Applicant Holder Full Name: BIOCON PHARMA LTD
Marketing Status: Prescription
Patent and Exclusivity Information
10MG
Marketing Status: Prescription
Active Ingredient: EVEROLIMUS
Proprietary Name: EVEROLIMUS
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 10MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A214182
Product Number: 004
Approval Date: Feb 11, 2021
Applicant Holder Full Name: BIOCON PHARMA LTD
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: EVEROLIMUS
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 10MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A214182
Product Number: 004
Approval Date: Feb 11, 2021
Applicant Holder Full Name: BIOCON PHARMA LTD
Marketing Status: Prescription
Patent and Exclusivity Information